{"id":4417,"date":"2019-03-26T05:11:06","date_gmt":"2019-03-26T05:11:06","guid":{"rendered":"https:\/\/www.erdheim-chester.org\/?post_type=study_trials&#038;p=4417"},"modified":"2019-11-12T15:29:11","modified_gmt":"2019-11-12T15:29:11","slug":"een-onderzoek-naar-plx8394-als-monotherapie-bij-patienten-met-gevorderde-inoperabele-solide-tumoren","status":"publish","type":"study_trials","link":"https:\/\/www.erdheim-chester.org\/nl\/study_trials\/a-study-of-plx8394-as-a-single-agent-in-patients-with-advanced-unresectable-solid-tumors\/","title":{"rendered":"Een onderzoek naar PLX8394 als monotherapie bij pati\u00ebnten met gevorderde, inoperabele solide tumoren"},"content":{"rendered":"<p><strong>Doel van het onderzoek:<\/strong>&nbsp; Het doel van dit klinisch onderzoek is om te achterhalen hoe PLX8394 kankercellen met mutaties in het BRAF-gen kan be\u00efnvloeden.  PLX8394 is ontwikkeld om mutaties in BRAF te blokkeren.  Deze mutaties kunnen kanker en de groei van kankercellen veroorzaken.\u00a0 Door deze mutaties te blokkeren, kan het geneesmiddel de kankercellen met de mutatie doden en\/of de groei van de tumor stoppen.<\/p>\n<p><strong>Sponsor:<\/strong>&nbsp; Plexxikon<\/p>\n<p><strong>Contactgegevens voor de proefperiode:<\/strong>&nbsp; Divya Sakamuri; 1-713-745-3296; dsakamuri@mdanderson.org of Filip Janku; 713-563-1930; FJanku@mdanderson.org<\/p>\n<p><strong>Gewenste betrokkenheid van de pati\u00ebnt:<\/strong>&nbsp; ECD-pati\u00ebnten ouder dan 18 jaar.<\/p>\n<p><strong>Bekende centra die ECD-pati\u00ebnten in het onderzoek opnemen:<\/strong>&nbsp; MD Anderson, Houston, Texas<\/p>\n<p><strong>ClinicalTrials.gov-identificatiecode:<\/strong>&nbsp; NCT02428712<\/p>","protected":false},"excerpt":{"rendered":"<p>Study Objective:&nbsp; The goal of this clinical research study is to learn how PLX8394 may affect cancer cells with mutations in the gene BRAF.&nbsp; PLX8394 is designed to block mutations [&hellip;]<\/p>\n","protected":false},"featured_media":0,"parent":0,"menu_order":0,"template":"","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","cybocfi_hide_featured_image":"","wds_primary_study_trials_cat":0,"_links_to":"","_links_to_target":""},"study_trials_cat":[32],"class_list":["post-4417","study_trials","type-study_trials","status-publish","hentry","study_trials_cat-drug-trial"],"_links":{"self":[{"href":"https:\/\/www.erdheim-chester.org\/nl\/wp-json\/wp\/v2\/study_trials\/4417","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.erdheim-chester.org\/nl\/wp-json\/wp\/v2\/study_trials"}],"about":[{"href":"https:\/\/www.erdheim-chester.org\/nl\/wp-json\/wp\/v2\/types\/study_trials"}],"wp:attachment":[{"href":"https:\/\/www.erdheim-chester.org\/nl\/wp-json\/wp\/v2\/media?parent=4417"}],"wp:term":[{"taxonomy":"study_trials_cat","embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/nl\/wp-json\/wp\/v2\/study_trials_cat?post=4417"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}